Join
Live feed
·
PRReleasevia Quantisnow
Trevi Therapeutics Inc. logo

Trevi Therapeutics Reports Positive Results from the Ph2b/3 PRISM Trial of Haduvio™ in the Treatment of Prurigo Nodularis

ByQuantisnow·Wall Street's wire, on your screen.
TRVI· Trevi Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track TRVI (Trevi Therapeutics Inc.) and more on Quantisnow.